Literature DB >> 31197380

Clinical spectrum, treatment and outcomes of uveal melanoma in a tertiary centre.

Wendy Wong1, Gangadhara Sundar1, Caroline Chee1, Paul Songbo Zhao1, Rajesh Rajagopalan2, Lingam Gopal1,3.   

Abstract

INTRODUCTION: We aimed to describe the clinical characteristics, diagnostic challenges, treatment patterns and outcomes of uveal melanoma (UM) in a tertiary care centre.
METHODS: This is a retrospective case series of 11 consecutive patients with UM who were managed in a tertiary referral centre between 2002 and 2017. Epidemiological, clinical, pathological and radiological characteristics were reviewed. Classification of choroidal melanoma as small, medium or large was based on the criteria established by the Collaborative Ocular Melanoma Study.
RESULTS: Mean age at presentation was 42.9 (range 27‒67) years. In 7 (64%) patients, a definitive diagnosis of UM was made after a mean follow-up period of 6.4 (range 1‒17) months. There were one, six and four patients with small-, medium- and large-sized choroidal melanomas, respectively. Treatment was enucleation in 5 (45.5%) patients, plaque brachytherapy in 4 (36.4%) patients, transpupillary thermotherapy in 1 (9.1%) patient, and observation in 1 (9.1%) patient. Median follow-up was 29 months. Metastatic disease developed in 5 (45.5%) patients at the mean age of 46.6 (range 38‒56) years, with median overall survival of 20 months. Genetic mutations in three patients were monosomy 3 (n = 2), and gain of 3q and 8q (n = 1).
CONCLUSION: Our study supports the finding that UM in Chinese and Asian Indian patients presents at a younger age than in Caucasians. Although it is rare, ophthalmologists should remain mindful of this life-threatening disease. We propose establishing a national and regional registry for ocular tumours with genetic information to characterise the disease spectrum in Southeast Asia. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  cytogenetics; metastasis; ocular oncology; uveal melanoma

Mesh:

Year:  2019        PMID: 31197380     DOI: 10.11622/smedj.2019054

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  6 in total

1.  Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea.

Authors:  Su-Kyung Jung; Young-Hoon Park; Dong-Ho Shin; Hak-Soo Kim; Jong-Hwi Jung; Tae-Hyun Kim; Sung Ho Moon
Journal:  PLoS One       Date:  2020-12-02       Impact factor: 3.240

2.  Specific human endogenous retroviruses predict metastatic potential in uveal melanoma.

Authors:  Matthew L Bendall; Jasmine H Francis; Alexander N Shoushtari; Douglas F Nixon
Journal:  JCI Insight       Date:  2022-05-09

3.  Necrosis of uveal melanoma post-COVID-19 vaccination.

Authors:  Ajeet M Wagle; Bing Cheng Wu; Lingam Gopal; Gangadhara Sundar
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

4.  A Novel and Easy-to-Promote Prognostic Model for Patients With Uveal Melanoma.

Authors:  Han Yue; Binbin Xu; Jian Gao; Yingwen Bi; Kang Xue; Jie Guo; Rui Zhang; Hui Ren; Yifei Yuan; Jiang Qian
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

Review 5.  Uveal Melanoma in Asians: A Review.

Authors:  Pradeep Manchegowda; Arun D Singh; Carol Shields; Swathi Kaliki; Parag Shah; Lingam Gopal; Pukhraj Rishi
Journal:  Ocul Oncol Pathol       Date:  2021-02-09

Review 6.  Iris Colour and the Risk of Developing Uveal Melanoma.

Authors:  Laurien E Houtzagers; Annemijn P A Wierenga; Aleid A M Ruys; Gregorius P M Luyten; Martine J Jager
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.